For primary prevention, aspirin was found to reduce serious vascular events by 0.07% per year compared with no aspirin, mainly due to a 0.05% reduction in nonfatal myocardial infarction. However aspirin significantly increased major gastrointestinal and other extracranial bleeds (0.1% per year with aspirin compared to 0.07% per year without aspirin). 3 For secondary prevention, aspirin yielded a greater absolute reduction in serious vascular events (6.7% vs 8.2% per year) and had a similar effect on major bleeds as seen in primary prevention. 3 The researchers concluded that when using aspirin for primary prevention, the absolute reduction in serious cardiovascular events is likely to be small, and is expected to be at least partially offset by a small increase in serious bleeds. They also stated that current evidence does not seem to support the routine use of aspirin in apparently healthy individuals with a more than moderate risk of CVD.
3
Aspirin for Asymptomatic Atherosclerosis (AAA) study Participants recruited for this study were asymptomatic but at risk of CVD as measured by ankle brachial index (ABI -the ratio of systolic pressure at the ankle to that of the arm). This also included those with elevated blood pressure or diabetes. 6, 7 They advised that low-dose aspirin should not be routinely initiated for primary prevention. And for those already taking it for primary prevention, either as prescribed or over-the-counter treatment, the decision to stop or continue treatment should be made with patients after fully informing them of the available evidence. 
How does this change practice in New Zealand?
The New Zealand Cardiovascular Guidelines recommend commencing low dose aspirin as secondary prevention in those with clinical CVD and stroke or TIA and as primary prevention for those with a five year CVD risk greater than 15%. Paracetamol was successful in reducing the risk of fever developing, however it also reduced the immune response to the vaccine, raising concern that the effectiveness of the vaccine may be reduced.
Although the prophylactic use of paracetamol brought about a reduction in immune response, using it once a fever developed did not appear to have the same effect.
This means that parents or caregivers should not be concerned about giving paracetamol to treat a raised temperature, or associated pain and irritability, should it develop post-immunisation.
The researchers concluded that although feverish reactions were significantly decreased by the use of paracetamol, prophylactic administration of it should not be routinely recommended since antibody responses to several vaccines were reduced.
